July 30, 2013
After the close Tuesday, Cubist Pharmaceuticals (NASDAQ: OPTR) for a combined total potential value of $1.619 billion if ...
June 24, 2013
Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
January 24, 2013
Cubist Pharmaceuticals Inc.'s (CBST) fourth quarter 2012 earnings (excluding special items) of 48 cents per share were in ...
December 26, 2012
Actelion (ALIOF) recently announced that it is moving forward with phase III development of cadazolid in patients suffering ...
December 4, 2012
Optimer Pharmaceuticals (OPTR) recently decided to collaborate with AstraZeneca (AZN) for the commercialization of Dificid ...
October 4, 2012
Currently, the Nasdaq has been relatively flat, the S&P 500 has risen 0.4% and the Dow has moved up 0.5%. The healthcare ...
September 18, 2012
So far today, the Nasdaq has increased 0.1%, the S&P 500 has been relatively flat and the Dow is trading up 0.1%. The healthcare ...
July 20, 2012
Cubist Pharmaceuticals, Inc.'s (CBST) second quarter 2012 earnings (excluding special items but including stock-based compensation ...
July 19, 2011
Cubist is hitting its targets, but it needs a more exciting pipeline.